Clinical Trial Update: Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

This clinical trial update notes that RK-582, a tankyrase inhibitor, is being studied in a Phase 1 trial for patients with unresectable metastatic colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• RK-582

Snippet

Sponsor: Eiji Shinozaki | Conditions: Unresectable Colorectal Neoplasm Metastasis | Phase 1 | Status: RECRUITING